Drug profile · INN
netupitant
AKYNZEO
netupitant (AKYNZEO) is a neurokinin 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — netupitant
- US status
- approved
- Class
- Alimentary tract and metabolism (A04)
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
netupitant (AKYNZEO) is a neurokinin 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurokinin 1 receptor antagonist
Primary target: Substance-P receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is netupitant?
netupitant (AKYNZEO) is a neurokinin 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for netupitant?
AKYNZEO is a marketed brand name for netupitant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of netupitant?
netupitant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.